サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：医薬品有効成分市場- 世界の市場規模、シェア、動向分析、機会、予測レポート、2019-2029年
市場調査レポート
商品コード
1310387

医薬品有効成分市場- 世界の市場規模、シェア、動向分析、機会、予測レポート、2019-2029年

Active Pharmaceutical Ingredients Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By API ; By Manufacturer ; By Type of Drug ; By Therapeutic Area ; By Potency ; Region
出版日: | 発行: Blueweave Consulting | ページ情報: 英文 400 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
医薬品有効成分市場- 世界の市場規模、シェア、動向分析、機会、予測レポート、2019-2029年
出版日: 2023年07月05日
発行: Blueweave Consulting
ページ情報: 英文 400 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品有効成分（API）市場規模は2029年までに3,250億米ドルに達する勢い

世界の慢性疾患の増加、ジェネリック医薬品製造の拡大、医薬品製造技術の進歩により、費用対効果の高い医薬品への需要が高まり、世界の医薬品有効成分（API）市場は活況を呈しています。

戦略コンサルティング・市場調査会社大手のBlueWeave Consultingは、最近の調査で、世界の医薬品有効成分（API）市場規模を2022年に2,324億米ドルと推定しました。2023年から2029年の予測期間中、世界の医薬品有効成分（API）市場規模はCAGR 5.69％で成長し、2029年には3,246億7,000万米ドルに達するとBlueWeaveは予測しています。心血管疾患、がん、糖尿病などの慢性疾患の世界の負担増は、効果的でコスト効率の高い治療オプションの需要を促進しています。APIは医薬品の骨格を形成しており、治療的介入の必要性が高まるにつれて、これらの医薬品を開発・製造するためのAPIの需要が増加します。さらに、製薬会社は革新的な医薬品や治療法を導入するため、研究開発活動に多額の投資を行っています。研究開発への注力の高まりは、医薬品開発の主な構成要素である原薬の需要をさらに押し上げると思われます。技術の進歩と新薬発見への投資の増加により、世界の医薬品有効成分（API）市場は今後数年間で大幅な成長が見込まれます。

本レポートの詳細な分析により、成長の可能性、今後の動向、世界の医薬品有効成分（API）市場の統計に関する情報を提供します。また、総市場規模の予測を促進する要因にも焦点を当てています。本レポートは、世界の医薬品有効成分（API）市場における最新の技術動向と、意思決定者が適切な戦略的意思決定を行うための業界洞察を提供することをお約束します。また、市場の成長促進要因・課題・競争力についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の医薬品有効成分（API）市場に関する洞察

  • 業界のバリューチェーン分析
  • DROC分析
    • 成長促進要因
      • ジェネリック医薬品の需要の増加
      • 慢性疾患の有病率の上昇
      • 新しいAPIの研究開発への注目の高まり
    • 抑制要因
      • 厳しい規制要件
      • 価格の変動性
    • 機会
      • 新興市場からの需要の拡大
      • 新技術の開発
    • 課題
      • 規制上の課題
      • ジェネリック医薬品との競合
  • 技術の進歩/最近の開発
  • 規制の枠組み
  • ポーターのファイブフォース分析

第4章 世界の医薬品有効成分（API）市場概要

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • API別
      • 合成API
      • 生物学的API
    • メーカー別
      • キャプティブ・メーカー
      • 販売業者メーカー
    • 薬の種類別
      • ブランド医薬品/革新医薬品
      • ジェネリック医薬品
    • 治療領域別
      • 心臓血管系
      • 中枢神経系（CNS）
      • 呼吸器系
      • 腫瘍学
      • 消化器系
      • その他
    • 効能別
      • 従来のAPI
      • HPAPI
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋（APAC）
      • ラテンアメリカ（LATAM）
      • 中東およびアフリカ（MEA）

第5章 北米の医薬品有効成分（API）市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • API別
    • メーカー別
    • 薬の種類別
    • 治療領域別
    • 効能別
    • 国別
      • 米国
      • カナダ

第6章 欧州の医薬品有効成分（API）市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • API別
    • メーカー別
    • 薬の種類別
    • 治療領域別
    • 効能別
    • 国別
      • ドイツ
      • 英国
      • イタリア
      • フランス
      • スペイン
      • ベルギー
      • ロシア
      • オランダ
      • その他欧州

第7章 アジア太平洋の医薬品有効成分（API）市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • API別
    • メーカー別
    • 薬の種類別
    • 治療領域別
    • 効能別
    • 国別
      • 中国
      • インド
      • 日本
      • 韓国
      • オーストラリアとニュージーランド
      • インドネシア
      • マレーシア
      • シンガポール
      • ベトナム
      • APACのその他の地域

第8章 ラテンアメリカの医薬品有効成分（API）市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • 国別
      • ブラジル
      • メキシコ
      • アルゼンチン
      • ペルー
      • 中南米のその他の地域

第9章 中東およびアフリカの医薬品有効成分（API）市場

  • 市場規模と予測、2019～2029年
    • 金額別
  • 市場シェアと予測
    • API別
    • メーカー別
    • 薬の種類別
    • 治療領域別
    • 効能別
    • 国別
      • サウジアラビア
      • アラブ首長国連邦
      • カタール
      • クウェート
      • 南アフリカ
      • ナイジェリア
      • アルジェリア
      • MEAのその他の地域

第10章 競合情勢

  • 主要企業とその製品のリスト
  • 世界の医薬品有効成分（API）市場シェア分析、2022年
  • 動作パラメータによる競合ベンチマーキング
  • 主要な戦略的展開（合併、買収、パートナーシップなど）

第11章 医薬品有効成分市場に対するCOVID-19の影響

第12章 企業プロファイル（会社概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先住所、戦略的展望、 SWOT分析）

  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Novartis International AG
  • Mylan N.V.
  • Aurobindo Pharma Ltd
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd
  • Merck & Co., Inc.
  • Lonza Group Ltd
  • Bristol-Myers Squibb
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Lupin Limited
  • Cipla Ltd
  • Other Prominent Players

第13章 主要な戦略的推奨事項

第14章 調査手法

  • 定性的調査
    • 一次および2次調査
  • 定量的調査
  • 市場内訳とデータの三角測量
    • 2次調査
    • 1次調査
  • 1次調査回答者の地域別内訳
  • 前提と制限
目次
Product Code: BWC19271

Global Active Pharmaceutical Ingredients (API) Market Size Booming to Touch USD 325 Billion by 2029.

Global active pharmaceutical ingredients (API) market is flourishing due to a high demand for cost-effective medicines driven by the increasing prevalence of chronic diseases across the world, expansion of generic drug manufacturing, and advancements in drug manufacturing technology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global active pharmaceutical ingredients (API) market size was worth USD 232.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global active pharmaceutical ingredients (API) market size to grow at a CAGR of 5.69% reaching a value of USD 324.67 billion by 2029. The rising global burden of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is driving the demand for effective and cost-efficient treatment options. APIs form the backbone of pharmaceutical drugs, and the growing need for therapeutic interventions will lead to an increased demand for APIs to develop and manufacture these medications. Moreover, pharmaceutical companies are investing heavily in R&D activities to introduce innovative drugs and therapies. The increasing focus on R&D will further drive the demand for APIs as they are the key components in drug development. With advancements in technology and increasing investments in novel drug discoveries, the global active pharmaceutical ingredients (API) market is expected to witness substantial growth in the coming years.

Increasing demand for generic drugs:

Generic drugs are cost-effective alternatives to branded drugs, offering the same therapeutic benefits at lower prices. This affordability makes them accessible to a larger population, driving their demand and subsequently boosting the API market. As patents expire for branded drugs, generic drug manufacturers can enter the market with their versions, utilizing APIs to produce these cost-effective alternatives. This creates opportunities for API manufacturers to supply the necessary ingredients for generic drug production. For example, when the patent for a popular branded drug expires, multiple generic manufacturers can develop their versions using the same API. This leads to increased competition, resulting in lower prices and wider availability of the drug. As a result, patients and healthcare providers can choose more affordable options, reducing healthcare costs, and increasing accessibility. A study by the World Health Organization (WHO) found that generic drugs can save up to 80% of the cost of branded drugs. The WHO also estimates that generic drugs could save the global healthcare system USD 200 billion per year. As a result, governments and healthcare systems worldwide are actively promoting the use of generic drugs to reduce healthcare expenditures. In some cases, regulations may even mandate the prescription of generic drugs whenever possible. This policy support further drives the demand for generic drugs and, consequently, the growth of global API market. The growing demand for generic drugs is also fueled by the increasing prevalence of chronic diseases globally. As the population ages and chronic conditions become more prevalent, the need for cost-effective treatment options rises. Generic drugs, enabled by APIs, play a vital role in meeting the increasing demand and providing affordable healthcare solutions.

Segmental Information:

Global Active Pharmaceutical Ingredients (API) Market - By Therapeutic Area:

Based on therapeutic area, the global active pharmaceutical ingredients (API) market is segmented into the cardiovascular system, central nervous system, respiratory system, oncology, gastrointestinal system, and others. The cardiovascular system segment held the largest market share in the global active pharmaceutical ingredients (API) market, due to the prominence of cardiovascular drugs and therapies. Cardiovascular diseases, including heart diseases, stroke, and hypertension, are prevalent worldwide and remain one of the leading causes of morbidity and mortality. The increasing incidence of cardiovascular disorders, coupled with the aging population and lifestyle changes, drives the demand for pharmaceutical interventions in this therapeutic area. As a result, there is a substantial need for API-based medications targeting the cardiovascular system. The cardiovascular API market benefits from the continuous development of innovative treatments and therapies. Furthermore, cardiovascular drugs often require long-term treatment, contributing to a sustained demand for APIs in the cardiovascular therapeutic area. Patients with cardiovascular conditions typically require medications that help regulate blood pressure, manage cholesterol levels, and prevent blood clots. As these drugs are frequently prescribed and used over extended periods, the demand for cardiovascular APIs remains high. Governments and healthcare organizations worldwide also prioritize cardiovascular health due to its substantial economic and healthcare burden. Public health initiatives and awareness campaigns further drive the demand for cardiovascular medications, boosting the market growth for cardiovascular APIs.

Impact of COVID-19 on Global Active Pharmaceutical Ingredients Market:

The COVID-19 pandemic had a mixed impact on the global active pharmaceutical ingredients (API) market. While the demand for certain APIs surged due to the production of drugs and vaccines to combat the virus, other segments experienced disruptions. Supply chain disruptions, restrictions on trade, and raw material shortages impacted API manufacturing and distribution. The increased focus on healthcare preparedness and vaccine development during the pandemic drove the demand for APIs. The pandemic also highlighted the importance of domestic API production, leading to efforts by governments to strengthen local manufacturing capabilities. Overall, the COVID-19 pandemic reshaped the API market dynamics, emphasizing the need for resilient supply chains and domestic manufacturing capacities.

Competitive Landscape:

The global active pharmaceutical ingredients (API) market is fragmented, with many players serving the market. The key players dominating the global active pharmaceutical ingredients (API) market include Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis International AG, Mylan N.V., Aurobindo Pharma Ltd, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Dr Reddy's Laboratories Ltd, Merck & Co., Inc., Lonza Group Ltd, Bristol-Myers Squibb, GlaxoSmithKline plc, AbbVie Inc., Lupin Limited, and Cipla Ltd. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Active Pharmaceutical Ingredients (API) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Active Pharmaceutical Ingredients (API) Market along with industry insights to help decision-makers make sound strategic decisions. The report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Active Pharmaceutical Ingredients (API) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing demand for generic drugs
      • 3.2.1.2. Rising prevalence of chronic diseases
      • 3.2.1.3. Growing focus on research and development of new APIs
    • 3.2.2. Restrains
      • 3.2.2.1. Stringent regulatory requirements
      • 3.2.2.2. Price volatility
    • 3.2.3. Opportunities
      • 3.2.3.1. Growing demand from emerging markets
      • 3.2.3.2. Development of new technologies
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory challenges
      • 3.2.4.2. Competition from generics
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Active Pharmaceutical Ingredients (API) Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By API
      • 4.2.1.1. Synthetic API
      • 4.2.1.2. Biological API
    • 4.2.2. By Manufacturer
      • 4.2.2.1. Captive Manufacturers
      • 4.2.2.2. Merchant Manufacturers
    • 4.2.3. By Type of Drug
      • 4.2.3.1. Branded/Innovator Drugs
      • 4.2.3.2. Generic Drugs
    • 4.2.4. By Therapeutic Area
      • 4.2.4.1. Cardiovascular System
      • 4.2.4.2. Central Nervous System (CNS)
      • 4.2.4.3. Respiratory System
      • 4.2.4.4. Oncology
      • 4.2.4.5. Gastrointestinal System
      • 4.2.4.6. Others
    • 4.2.5. By Potency
      • 4.2.5.1. Traditional API
      • 4.2.5.2. HPAPI
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Active Pharmaceutical Ingredients (API) Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By API
    • 5.2.2. By Manufacturer
    • 5.2.3. By Type of Drug
    • 5.2.4. By Therapeutic Area
    • 5.2.5. By Potency
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By API
      • 5.2.6.1.2. By Manufacturer
      • 5.2.6.1.3. By Type of Drug
      • 5.2.6.1.4. By Therapeutic Area
      • 5.2.6.1.5. By Potency
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By API
      • 5.2.6.2.2. By Manufacturer
      • 5.2.6.2.3. By Type of Drug
      • 5.2.6.2.4. By Therapeutic Area
      • 5.2.6.2.5. By Potency

6. Europe Active Pharmaceutical Ingredients (API) Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By API
    • 6.2.2. By Manufacturer
    • 6.2.3. By Type of Drug
    • 6.2.4. By Therapeutic Area
    • 6.2.5. By Potency
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By API
      • 6.2.6.1.2. By Manufacturer
      • 6.2.6.1.3. By Type of Drug
      • 6.2.6.1.4. By Therapeutic Area
      • 6.2.6.1.5. By Potency
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By API
      • 6.2.6.2.2. By Manufacturer
      • 6.2.6.2.3. By Type of Drug
      • 6.2.6.2.4. By Therapeutic Area
      • 6.2.6.2.5. By Potency
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By API
      • 6.2.6.3.2. By Manufacturer
      • 6.2.6.3.3. By Type of Drug
      • 6.2.6.3.4. By Therapeutic Area
      • 6.2.6.3.5. By Potency
      • 6.2.6.4. France
      • 6.2.6.4.1. By API
      • 6.2.6.4.2. By Manufacturer
      • 6.2.6.4.3. By Type of Drug
      • 6.2.6.4.4. By Therapeutic Area
      • 6.2.6.4.5. By Potency
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By API
      • 6.2.6.5.2. By Manufacturer
      • 6.2.6.5.3. By Type of Drug
      • 6.2.6.5.4. By Therapeutic Area
      • 6.2.6.5.5. By Potency
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By API
      • 6.2.6.6.2. By Manufacturer
      • 6.2.6.6.3. By Type of Drug
      • 6.2.6.6.4. By Therapeutic Area
      • 6.2.6.6.5. By Potency
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By API
      • 6.2.6.7.2. By Manufacturer
      • 6.2.6.7.3. By Type of Drug
      • 6.2.6.7.4. By Therapeutic Area
      • 6.2.6.7.5. By Potency
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By API
      • 6.2.6.8.2. By Manufacturer
      • 6.2.6.8.3. By Type of Drug
      • 6.2.6.8.4. By Therapeutic Area
      • 6.2.6.8.5. By Potency
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By API
      • 6.2.6.9.2. By Manufacturer
      • 6.2.6.9.3. By Type of Drug
      • 6.2.6.9.4. By Therapeutic Area
      • 6.2.6.9.5. By Potency

7. Asia-Pacific Active Pharmaceutical Ingredients (API) Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By API
    • 7.2.2. By Manufacturer
    • 7.2.3. By Type of Drug
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By Potency
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By API
      • 7.2.6.1.2. By Manufacturer
      • 7.2.6.1.3. By Type of Drug
      • 7.2.6.1.4. By Therapeutic Area
      • 7.2.6.1.5. By Potency
      • 7.2.6.2. India
      • 7.2.6.2.1. By API
      • 7.2.6.2.2. By Manufacturer
      • 7.2.6.2.3. By Type of Drug
      • 7.2.6.2.4. By Therapeutic Area
      • 7.2.6.2.5. By Potency
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By API
      • 7.2.6.3.2. By Manufacturer
      • 7.2.6.3.3. By Type of Drug
      • 7.2.6.3.4. By Therapeutic Area
      • 7.2.6.3.5. By Potency
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By API
      • 7.2.6.4.2. By Manufacturer
      • 7.2.6.4.3. By Type of Drug
      • 7.2.6.4.4. By Therapeutic Area
      • 7.2.6.4.5. By Potency
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By API
      • 7.2.6.5.2. By Manufacturer
      • 7.2.6.5.3. By Type of Drug
      • 7.2.6.5.4. By Therapeutic Area
      • 7.2.6.5.5. By Potency
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By API
      • 7.2.6.6.2. By Manufacturer
      • 7.2.6.6.3. By Type of Drug
      • 7.2.6.6.4. By Therapeutic Area
      • 7.2.6.6.5. By Potency
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By API
      • 7.2.6.7.2. By Manufacturer
      • 7.2.6.7.3. By Type of Drug
      • 7.2.6.7.4. By Therapeutic Area
      • 7.2.6.7.5. By Potency
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By API
      • 7.2.6.8.2. By Manufacturer
      • 7.2.6.8.3. By Type of Drug
      • 7.2.6.8.4. By Therapeutic Area
      • 7.2.6.8.5. By Potency
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By API
      • 7.2.6.9.2. By Manufacturer
      • 7.2.6.9.3. By Type of Drug
      • 7.2.6.9.4. By Therapeutic Area
      • 7.2.6.9.5. By Potency
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By API
      • 7.2.6.10.2. By Manufacturer
      • 7.2.6.10.3. By Type of Drug
      • 7.2.6.10.4. By Therapeutic Area
      • 7.2.6.10.5. By Potency

8. Latin America Active Pharmaceutical Ingredients (API) Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
      • 8.2.1.1. By API
      • 8.2.1.2. By Manufacturer
      • 8.2.1.3. By Type of Drug
      • 8.2.1.4. By Therapeutic Area
      • 8.2.1.5. By Potency
    • 8.2.2. By Country
      • 8.2.2.1. Brazil
      • 8.2.2.1.1. By API
      • 8.2.2.1.2. By Manufacturer
      • 8.2.2.1.3. By Type of Drug
      • 8.2.2.1.4. By Therapeutic Area
      • 8.2.2.1.5. By Potency
      • 8.2.2.2. Mexico
      • 8.2.2.2.1. By API
      • 8.2.2.2.2. By Manufacturer
      • 8.2.2.2.3. By Type of Drug
      • 8.2.2.2.4. By Therapeutic Area
      • 8.2.2.2.5. By Potency
      • 8.2.2.3. Argentina
      • 8.2.2.3.1. By API
      • 8.2.2.3.2. By Manufacturer
      • 8.2.2.3.3. By Type of Drug
      • 8.2.2.3.4. By Therapeutic Area
      • 8.2.2.3.5. By Potency
      • 8.2.2.4. Peru
      • 8.2.2.4.1. By API
      • 8.2.2.4.2. By Manufacturer
      • 8.2.2.4.3. By Type of Drug
      • 8.2.2.4.4. By Therapeutic Area
      • 8.2.2.4.5. By Potency
      • 8.2.2.5. Rest of LATAM
      • 8.2.2.5.1. By API
      • 8.2.2.5.2. By Manufacturer
      • 8.2.2.5.3. By Type of Drug
      • 8.2.2.5.4. By Therapeutic Area
      • 8.2.2.5.5. By Potency

9. Middle East & Africa Active Pharmaceutical Ingredients (API) Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By API
    • 9.2.2. By Manufacturer
    • 9.2.3. By Type of Drug
    • 9.2.4. By Therapeutic Area
    • 9.2.5. By Potency
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By API
      • 9.2.6.1.2. By Manufacturer
      • 9.2.6.1.3. By Type of Drug
      • 9.2.6.1.4. By Therapeutic Area
      • 9.2.6.1.5. By Potency
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By API
      • 9.2.6.2.2. By Manufacturer
      • 9.2.6.2.3. By Type of Drug
      • 9.2.6.2.4. By Therapeutic Area
      • 9.2.6.2.5. By Potency
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By API
      • 9.2.6.3.2. By Manufacturer
      • 9.2.6.3.3. By Type of Drug
      • 9.2.6.3.4. By Therapeutic Area
      • 9.2.6.3.5. By Potency
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By API
      • 9.2.6.4.2. By Manufacturer
      • 9.2.6.4.3. By Type of Drug
      • 9.2.6.4.4. By Therapeutic Area
      • 9.2.6.4.5. By Potency
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By API
      • 9.2.6.5.2. By Manufacturer
      • 9.2.6.5.3. By Type of Drug
      • 9.2.6.5.4. By Therapeutic Area
      • 9.2.6.5.5. By Potency
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By API
      • 9.2.6.6.2. By Manufacturer
      • 9.2.6.6.3. By Type of Drug
      • 9.2.6.6.4. By Therapeutic Area
      • 9.2.6.6.5. By Potency
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By API
      • 9.2.6.7.2. By Manufacturer
      • 9.2.6.7.3. By Type of Drug
      • 9.2.6.7.4. By Therapeutic Area
      • 9.2.6.7.5. By Potency
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By API
      • 9.2.6.8.2. By Manufacturer
      • 9.2.6.8.3. By Type of Drug
      • 9.2.6.8.4. By Therapeutic Area
      • 9.2.6.8.5. By Potency

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Active Pharmaceutical Ingredients (API) Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Active Pharmaceutical Ingredients Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Teva Pharmaceutical Industries Ltd
  • 12.2. Pfizer Inc.
  • 12.3. Novartis International AG
  • 12.4. Mylan N.V.
  • 12.5. Aurobindo Pharma Ltd
  • 12.6. Sun Pharmaceutical Industries Ltd
  • 12.7. Boehringer Ingelheim GmbH
  • 12.8. Dr. Reddy's Laboratories Ltd
  • 12.9. Merck & Co., Inc.
  • 12.10. Lonza Group Ltd
  • 12.11. Bristol-Myers Squibb
  • 12.12. GlaxoSmithKline plc
  • 12.13. AbbVie Inc.
  • 12.14. Lupin Limited
  • 12.15. Cipla Ltd
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations